Table 4.

Gene-gene interaction analysis between NAT2, NQ01, and CYP2E1 polymorphisms and acute lymphoblastic leukemia risk.

Number of factors	Model	TA	TBA	CVC	OR (CI 95%)	p-value°
1	NAT2-rs1799929*	0.585	0.585	10/10	1.99 (1.46–2.31)	<0.0001
2	NAT2-rs1801280, NAT2-rs1799929	0.614	0.6031	8/10	5.42 (3.26–9.02)	<0.0001
3	NAT2-rs1801280, NAT2-rs1799929, NAT2-rs1208**	0.644	0.637	10/10	6.59 (4.05, 10.71)	<0.0001
4	NAT2-rs1041983, NAT2-rs1801280, NAT2-rs1799929, NAT2-rs1799931	0.662	0.5909	6/10	3.75 (2.71–5.19)	<0.0001
5	NAT2-rs1041983, NAT2-rs1799929, NAT2-rs1799931, NQ01-rs1800566, CYP2E1-rs3813867	0.689	0.568	3/10	6.19 (4.18–9.15	<0.0001
6	NAT2-rs1041983, NAT2-rs1799929, NAT2-rs1208, NAT2-rs1799931, NQ01-rs1800566, CYP2E1-rs3813867	0.715	0.549	5/10	5.89 (4.21–8.26)	<0.0001
7	NAT2-rs1041983, NAT2-rs1799929, NAT2-rs1799930, NAT2-rs1208, NAT2-rs1799931, NQ01-rs1800566, CYP2E1-rs3813867	0.738	0.5751	4/10	7.33 (5.19–10.35)	<0.0001
8	NAT2-rs1041983, NAT2-rs1801280, NAT2-rs1799929, NAT2-rs1799930, NAT2-rs1208, NAT2-rs1799931, NQ01-rs1800566, CYP2E1-rs3813867	0.754	0.578	10/10	8.85 (6.23–12.59)	<0.0001

Best one-to-eight-locus model of the NAT2-NQ01-CY2E1 gene–gene interactions with cross-validation consistency (CVC) and prediction error per the n-locus model that have been obtained by the multifactor- dimensionality reduction (MDR) of our data set. TA, training balance accuracy; TBA, testing balance accuracy; *The best one factor model and **The best multilocus model. °P-values from whole statistics data set. Bold values indicate the best single* and models.